Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study to Determine the Role of Ixazomib as an Augmented Conditioning Therapy in Salvage Autologous Stem Cell Transplant (ASCT) and as a Post-ASCT Consolidation and Maintenance Strategy in Patients With Relapsed Multiple Myeloma

NCT03562169 is registered in ClinicalTrials.gov with University of Leeds as lead sponsor.

NCT NCT03562169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03562169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study to Determine the Role of Ixazomib as an Augmented Conditioning Therapy in Salvage Autologous Stem Cell Transplant (ASCT) and as a Post-ASCT Consolidation and Maintenance Strategy in Patients With Relapsed Multiple Myeloma
Lead sponsor
University of Leeds
Phase
Phase 3
Overall status
Recruiting
Start date
March 20, 2017
Completion date
March 31, 2027
Enrollment
406 (estimated)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma